8-K: Health Catalyst Appoints Largest Shareholder's CEO to Board
Board and Governance Update
Health Catalyst, Inc. announced the appointment of Matt Arens, CEO of its largest shareholder First Light Asset Management, to its Board of Directors, alongside a voting and confidentiality agreement.
Summary
- Health Catalyst, Inc. (HCAT) appointed Matt Arens, CEO and Founder of First Light Asset Management, LLC, to its Board of Directors, effective December 1, 2025.
- First Light Asset Management is the Company's largest stockholder, and together with Mr. Arens, they collectively own approximately 13.9 million shares, representing about 19% of outstanding common stock.
- Mr. Arens' appointment expanded the Board from eight to nine directors.
- A letter agreement was executed, requiring First Light and Mr. Arens to vote their shares in favor of Board-nominated directors and against unapproved proposals, with exceptions for extraordinary transactions or charter/bylaw amendments.
- Mr. Arens will waive director compensation, except for out-of-pocket expense reimbursement.
- Matthew Kolb, a director since 2023, will not stand for re-election at the 2026 annual meeting, with no disagreements cited.
- The Board size will revert to eight directors prior to the 2026 annual meeting.
Sentiment
Score: 7
Explanation: The appointment of a significant institutional investor's CEO to the board, coupled with his strong belief in the company's undervaluation and potential for appreciation, is a positive signal. The voting agreement also suggests a commitment to aligning shareholder and board interests. The departure of another director is noted but stated to be without disagreement, mitigating potential negative sentiment.
Positives
- The appointment of Matt Arens, CEO of the largest shareholder (First Light Asset Management, owning ~19% of shares), to the Board of Directors.
- Mr. Arens brings nearly 30 years of investment experience, with over 15 years managing dedicated healthcare portfolios, and expertise in capital markets and shareholder value creation.
- First Light's small-cap growth strategy was ranked #1 by PSN/Informa for the period spanning September 2008 through September 2025.
- Mr. Arens believes the market is not recognizing significant value in Health Catalyst, citing a low multiple on EBITDA, high free cash flow generation potential, and valuable data.
- The voting agreement ensures alignment between the largest shareholder and the Board on most governance matters.
- Mr. Arens is waiving director compensation, except for expense reimbursement.
Negatives
- Matthew Kolb, a director since 2023, will not stand for re-election at the 2026 annual meeting, leading to a reduction in board size, though no disagreements were cited.
Risks
- Important risks and uncertainties that could cause actual results to differ materially from Health Catalyst's expectations, plans and prospects are detailed in the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, and the Annual Report on Form 10-K for the year ended December 31, 2024. No new specific risks are detailed in this 8-K.
Future Outlook
Management believes Matt Arens' contributions will be invaluable in advancing the mission of measurable healthcare improvement, sharpening strategic focus, and driving significant shareholder value. Mr. Arens himself expresses strong conviction that the market is currently undervaluing Health Catalyst, seeing extraordinary appreciation potential due to a low EBITDA multiple, high free cash flow generation potential, and the inherent value of the company's data.
Management Comments
- "His depth of experience in capital markets, particularly in identifying meaningful shareholder value creation opportunities within microto mid-cap publicly traded healthcare companies, adds an important perspective to our Board." John Kane, independent Chair of Health Catalyst's Board.
- "We believe Matts contributions will be invaluable as we advance our mission to enable measurable healthcare improvement, sharpen our strategic focus, and seek to drive significant value for our shareholders." Dan Burton, CEO of Health Catalyst.
- "I am humbled to be invited to join Health Catalysts board and hope my contributions will be additive to the board's efforts." Matt Arens.
- "We at First Light strongly feel the market is not recognizing the significant value embedded within Health Catalysts business. The combination of a low multiple on EBITDA, high free cash flow generation potential, and the incredible value of the data Health Catalyst possesses leads us to believe the opportunity for appreciation in Health Catalyst shares is extraordinary." Matt Arens.
- "Matthew has been an extraordinary leader in advancing data-informed healthcare improvements and has had a significant and impactful presence on the Health Catalyst Board." John Kane, independent Chair of Health Catalyst's Board, regarding Matthew Kolb.
Industry Context
The appointment of a major institutional investor's CEO to the board of a healthcare technology company like Health Catalyst reflects a growing trend of increased shareholder activism and a focus on enhancing shareholder value. In the data and analytics sector for healthcare, leveraging expertise in capital markets and identifying undervalued assets can be crucial for strategic growth and market positioning. The emphasis on 'measurable healthcare improvement' and 'AI-enabled data and analytics solutions' aligns with broader industry shifts towards value-based care and digital transformation.
Comparison to Industry Standards
- First Light's longest-running separately managed account strategy was ranked the #1 U.S. small-cap growth strategy by PSN/Informa for the period spanning its inception in September 2008 through September 30, 2025.
- Mr. Arens' assessment of Health Catalyst's "low multiple on EBITDA" and "high free cash flow generation potential" suggests a belief that the company is undervalued compared to its peers or intrinsic value, though no specific comparable companies or benchmarks are named in the filing.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | N/A | Mathew (Matt) Arens | 2025-12-01 | Appointment to fill a newly created vacant Board seat due to Board expansion, representing the Company's largest stockholder. |
| Director | Matthew Kolb | N/A | Prior to 2026 annual meeting | Will not stand for re-election at the 2026 annual meeting of stockholders; no disagreements cited. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Expansion | The Board of Directors expanded from eight to nine directors to accommodate the appointment of Matt Arens. | 2025-12-01 | Increases board size to incorporate a significant shareholder's representative, potentially enhancing oversight and strategic alignment with major investor interests. |
| Voting Agreement | A letter agreement was entered into with First Light Asset Management, LLC and Matt Arens, committing them to vote their shares in alignment with Board recommendations on most matters, with exceptions for extraordinary transactions or charter/bylaw amendments. | 2025-12-01 | Formalizes a voting alignment with the largest shareholder, potentially stabilizing governance and reducing proxy contest risks, while allowing discretion on major structural changes. |
| Confidentiality Agreement | Matt Arens and First Light Asset Management, LLC entered into a confidentiality agreement regarding non-privileged Company information, with strict rules on disclosure and use. | 2025-12-01 | Ensures that sensitive company information shared with the director and his firm remains protected, balancing transparency with proprietary information security. |
| Board Size Reduction | The Board approved a reduction in its size from nine to eight directors, effective immediately prior to the 2026 annual meeting of stockholders, following Matthew Kolb's decision not to stand for re-election. | Prior to 2026 annual meeting | Adjusts board composition following a director's departure, maintaining an eight-member board which is a common and often efficient size for corporate governance. |
Related Party Transactions
- No transactions with the Company exceeding $120,000 in which Mr. Arens had or will have a direct or indirect material interest have occurred since the beginning of the Company's last fiscal year, and none are currently proposed.
Stakeholder Impact
- Shareholders: The appointment of a representative from the largest shareholder (19% stake) to the board, along with a voting agreement, suggests increased alignment between major shareholder interests and board decisions. This could be seen as positive for shareholder value creation, especially given Mr. Arens' stated belief in the company's undervaluation.
- Management: The new director brings a strong financial and investment perspective, which could influence strategic direction and operational focus towards shareholder value.
- Employees: No direct impact mentioned, but a stronger focus on shareholder value and strategic clarity could indirectly affect company performance and stability.
- Customers/Suppliers/Creditors: No direct impact mentioned.
Next Steps
- Mr. Arens will serve as a Class I director until the Company's 2026 annual meeting of stockholders.
- Matthew Kolb's term will end immediately prior to the commencement of the 2026 annual meeting of stockholders.
- The Board size will be reduced from nine to eight directors, effective immediately prior to the commencement of the 2026 annual meeting of stockholders.
Key Dates
| Date | Description |
|---|---|
| 2008-09-01 | Inception of First Light's longest-running separately managed account strategy. |
| 2013-01-01 | Matt Arens founded First Light Asset Management. |
| 2019-01-01 | First Light Asset Management became shareholders of Health Catalyst since its IPO. |
| 2023-01-01 | Matthew Kolb began serving as a Health Catalyst director. |
| 2024-12-31 | End of fiscal year for which the Annual Report on Form 10-K was filed on February 26, 2025. |
| 2025-09-25 | End of period for which First Light's small-cap growth strategy was ranked #1 by PSN/Informa. |
| 2025-09-30 | End of fiscal quarter for which the Quarterly Report on Form 10-Q was filed on November 10, 2025. |
| 2025-12-01 | Date of earliest event reported; Matt Arens appointed to the Board; Board expanded from 8 to 9 directors; Letter agreement entered into between Health Catalyst, First Light, and Matt Arens; Board determined not to renominate Matthew Kolb. |
| 2025-12-02 | Company issued a press release announcing Mr. Arens' appointment and Mr. Kolb's non-re-election; Date of signing of the 8-K report. |
| 2026-01-01 | Matthew Kolb's term as director will end immediately prior to the commencement of the 2026 annual meeting of stockholders. |
| 2026-01-01 | Board size will be reduced from nine to eight directors, effective immediately prior to the commencement of the 2026 annual meeting of stockholders. |
| 2026-01-01 | Matt Arens will serve as a Class I director until the Company's 2026 annual meeting of stockholders. |
Recommendation
buyThe appointment of Matt Arens, CEO of the largest shareholder First Light Asset Management, to the Board is a strong positive signal. His deep expertise in capital markets and healthcare, coupled with his firm's top-ranked investment strategy, brings valuable perspective. Crucially, Mr. Arens explicitly states his belief that Health Catalyst is significantly undervalued, citing a low EBITDA multiple, high free cash flow potential, and valuable data. This indicates a strong internal advocate for shareholder value creation. The voting agreement further aligns the interests of a major institutional investor with the company's governance. While one director is departing, the stated lack of disagreement mitigates concern. This move suggests a concerted effort to unlock and communicate the company's intrinsic value, making it an attractive 'buy' for investors seeking long-term appreciation.
Keywords
Health Catalyst, HCAT, Board of Directors, Matt Arens, First Light Asset Management, Corporate Governance, Shareholder Value, Healthcare Technology, SEC Filing, 8-K, Director Appointment, Voting Agreement, Confidentiality Agreement
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.